A personalized intervention to prevent depression in primary care: cost-effectiveness study nested into a clustered randomized trial

Table 2 Incremental cost-effectiveness ratio (ICER)-adjusted analysis: main scenarios

Effect	Ajdusted^a mean difference (95% bootstrapped CI) and ICER
Main Outcome
Societal perspective
Incremental cost	–16.38(–615 to 503)
Incremental QALY	0.02(–0.00 to 0.04)
ICER (cost per QALY gained)	Dominant
National Health perspective
Incremental cost	23.88 (–149 to 215)
Incremental QALY	0.02 (–0.00 to 0.04)
ICER (cost per QALY gained)	€1327/QALY
Secondary outcomes
Societal perspective
Incremental cost	–16.38(–615 to 503)
Incremental QALY-VAS	0.02 (0.01 to 0.03)
ICER (cost per QALY-VAS gained)	Dominant
National Health perspective
Incremental cost	23.88 (–149 to 215)
Incremental QALY-VAS	0.02(0.01 to 0.03)
ICER (cost per QALY-VAS gained)	€1085/QALY

^aAll the analyses have been adjusted by baseline variables: employment status, owner/occupier of an accommodation, perception of safety inside/outside the home, anxiety disorder, experiences of discrimination,city, in addition to the risk of depression and the respective baseline value (i.e. costs or QALYs)

ISSN: 1741-7015